Note: Descriptions are shown in the official language in which they were submitted.
CA 02132833 2002-09-05
-1-
HEPATITIS VACCINES CONTAINING 3-O-DEACYLATED MONOPHOSPHORYL LIPID A
The present invention relates to novel vaccine formulations, methods for
preparing
them and to their use in therapy. In particular the present invention relates
to novel
formulations for treating Hepatitis infections and to combination vaccine
formulations
including a Hepatitis vaccine component.
Viral hepatitis, caused by the A, B, C, D, and E hepatitis viruses, is a very
common
viral illness. Via the B and C viruses, in particular, it is also responsible
for many
cases of liver cancer. Thus the development of effective vaccines is critical
and,
despite notable sucxesses, is still an on-going task. A review on modern
hepatitis
vaccines, including a number of key references, may be found in the Lancet,
May
12th 1990 at page 1142 ff (Prof A.L.W.F. Eddleston). See also 'Viral Hepatitis
and
Liver Disease' (Vyas, B.N., Dienstag, J.L., and Hoofnagle, J.H., eds, Grune
and
Stratton, Inc. ( 1984) and 'Viral Hepatitis and Liver Disease' (Proceedings of
the 199(?
International Symposium, eds F.B. Hollinger, S.M. Lemon and H. Margolis,
published by Williams and Willdns).
As used herein the expression 'hepatitis antigen' is used to refer to any
antigenic
material derived from a hepatitis virus which may be usod to induce immunity
to the
virus in humans. The hepatitis antigen may be, for example, a polypeptide
obtained
by recombinant DNA techniques or an attenuated strain of hepatitis virus which
has
-w optionally been inactivated by known methods. The invention extends to all
hepatitis
antigens, whether A, B, C, D, or E, examples of which are discussed below.
Infection with hepatitis A virus (HAV) is a widespread problem but vaccines
which
can be used for mass immunisation are available, for example the product
'Havrix' ~'
(SmithKline Beecham Biologicals) which is a Idllod attenuated vaccine obtained
from
the HM-175 strain of HAV [see 'Inactivated Candidate Vaccines for Hepatitis A'
by
F.E. Andre, A Hepburn and E.D'Hondt, Prog Med. Virot. Vol 37, pages 72-95
(1990) and the product monograph 'Havrix' published by SmithKline Beecham
Biologicals (1991)].
Flehmig et al (toe cit., pages 56-71 ) have reviewed the clinical aspects,
virology,
immunology and epidemiology of Hepatitis A and discussed approaches to the
development of vaccines against this common viral infection.
*Trade-mark
CA 02132833 2002-09-05
-2-
As used herein the expression 'HAV antigen' refers to any antigen capable of
stimulating neutralising antibody to HAV in humans. The HAV antigen may
comprise live attenuated virus particles or inactivated attenuated virus
particles or
may be, for example an HAV capsid or HAV viral protein, which may conveniently
be obtained by recombinant DNA technology.
Infection with hepatitis B virus (HBV) is a widespread problem but vaccines
which
can be used for mass immunisation are now available, for example the product
'Engerix-B' (SmithKline Beecham plc) which is obtained by genetic engineering
techniques.
The preparation of Hepatitis B surface antigen (I-~sAg) is well documented.
See, for
example, Harford et al in Develop. Biol. Standard 54, page 125 (1983), Gregg
et al
in Biotechnology, 5, page 479 (1987), EP-A- 0 226 846, EP-A-0 299 108 and
I S tzferences therein.
As used herein the expression 'Hepatitis B surface antigen' or'I~sAg' includes
any
HBsAg antigen or fragment thereof displaying the antigenicity of HBV surface
antigen. It will be understood that in addition to the 226 amino acid sequence
of the
HBsAg S antigen (sec Tiollais et al, Nature, 317, 489 (1985) and references
therein)
HBsAg as herein described may, if desired, contain all ar pan of a pre-S
sequence as
described in the above references and in EP-A- 0 278 940. In particular the
HBsAg
may comprise a polypeptide comprising an amino acid sequencx comprising
residues
12-52 followed by residues 133-145 followed by residues 175-400 of the L-
protein of
HBsAg relative to the open reading frame on a Hepatitis B virus of ad serotype
(this
polypeptidc is referred to as L*; see EP 0 414 374).. HBsAg within the scope
of the
invention may also include the preS 1-preS2 -S polypcptide described in EP
0198 474
(Endotronics) or analogues thtreof such as those described in EP 0 304 578 (Mc
Cormick and Jones). HBsAg as herein described can also refer to mutants, for
example the 'escape mutant' described in WO 91/14703 or European Patent
Application Publication Number 0 511 855 A1, especially HBsAg wherein the
amino
acid substitution at position 145 is to arginine from glycine.
Normally the HBsAg will be in particle form. The particles may comprise for
example S protein alone or may be composite panicles, for example (L*,S) where
L*
is as defined above and S denotes the S-protein of HBsAg. The said particle is
advantageously in the farm in which it is expressed in yeast
*Trade-mark
~O 93/19780 p ~ PCT/EP93/00712
~~~~~~ek
-3-
Hepatitis C virus (HCV) is specifically discussed in GB 2 212 S11B and
references
therein. It has been reported that vaccines may be prepared from one or more
immunogenic polypeptides derived from HCV c DNA.
Hepatitis D virus is discussed in 'Viral Hepatitis and Liver Disease' ( 1990
Symposium
(loc. cit.).
Hepatitis E virus (HEV) is specifically discussed in WO 89/12462 and
references
therein. An example of a vaccine composition includes, in a pharmacologically
acceptable adjuvant, a recombinant protein or protein mixture derived from
HEV.
Whilst experimental and commercially available Hepatitis vaccines, for example
Havrix and Engerix-B, afford excellent results it is an accepted fact that an
optimal
vaccine needs to stimulate not only neutralising antibody but also needs to
stimulate
as effectively as possible cellular immunity mediated through T-cells. There
also
exists a need for combination vaccines containing a Hepatitis component to
stimulate
cellular immunity in this way. The present invention achieves these aims.
The present invention provides a vaccine comprising a hepatitis antigen in
conjunction with 3-O-deacylated monophosphoryl lipid A (abbreviated herein to
MPL) and a suitable carrier.
3-O-deacylated monophosphoryl lipid A (or 3 De-O-acylated monophosphoryl lipid
A) has formerly been termed 3D-MPL or d3-MPL to indicate that position 3 of
the
inducing end glucosamine is de-O-acylated. For preparation, see GB 2 220 211 A
Chemically it is a mixture of 3-deacylated monophosphoryl lipid A with 4, 5 or
6
acylated chains. Herein the term 3D-MPL (or d3-MPL) is abbreviated to MPL
since
'MPL' is a Registered Trademark of Ribi Immunochem.,Montana which is used by
Ribi to denote unambiguously their 3-O-deacylated monophosphoryl lipid A
product.
GB 2 220 21 1A mentions that the endotoxicity of the previously used
enterobacterial
lipopolysacharides (LPS) is reduced while the immunogenic properties ain
conserved.
However GB 2 220 211 cited these findings merely in connection with bacterial
(Cram negative) systems. At the priority date of the present invention the
suitability
of 3-Deacylated monophosphoryl lipid A as an adjuvant for a vaccine containing
a
hepatitis viral antigen had not been suggested.
o~ se~~-tre ~~r-c cu~cT
CA 02132833 2002-09-05
-4-
Surprisingly, however, it has been found that vaccine compositions according
to the '~-
invention comprising hepatitis viral antigens have particularly advantageous
properties as described herein.
A particular advantage is that the vaccine formulations of the invention are
very
effective in inducing protective immunity, even with very low doses of
antigen.
They provide excellent protection against primary infection and stimulate
advantageously both specific humoral (neutralising antibodies) and also
effector cell
modiated (DTH) immune responses.
A further important advantage is that vaccine compositions according to the
invention
may also be used as therapeutic vaccines.
The MPL as defined above will normally be present in the range of 10-100ug,
preferably 25-SOug ptr dose wherein the Hepatitis antigen will be typically
present in
a range 2-SOug per dose.
The carrier may be an oil in water emulsion, a lipid vehicle, or alum
(aluminium salt).
Non-toxic oil in water emulsions preferably contain a non-toxic oil, e.g.
squalene and
an emulsifier such as Tween 80, in an aqueous cannier. The aqueous carrier may
be,
for example, phosphate buffered saline.
One embodiment of the invention is HAV antigen (for example as in Havrix) in
admixture with MPL and aluminium hydroxide as described hereinbelow.
A further embodiment of the invention is HBsAg S antigen (for example as in
Engerix-B) in admixture with MPL and aluminium hydroxide as described
hercinbelow.
A further specific embodiment of the invention is HBsAg antigen as (L*,S)
particles,
defined heseinabove, in admixture with MPL and aluminium hydroxide.
In the above embodiments an oil in water emulsion may be used instead of alum.
Othtr embodiments arc given in the examples hereinbelow.
*Trade-mark
O 93/19780 ~ ~ ~ ~ ~ ~ PCT/EP93/00712
-5-
The invention in a further aspect provides a vaccine formulation as described
herein
for use in medical therapy, particularly for use in the treatment or
prophylaxis of
hepatitis viral infections. In a preferred aspect the vaccine according to the
invention
is a therapeutic vaccine useful for the treatment of ongoing hepatitis
infections, more
especially hepatitis B and/or hepatitis C infections in humans suffering
therefrom.
In view of the surprisingly efficaceous results obtained, in a further
preferred aspect
the invention provides a vaccine composition for the treatment or prophylaxis
of
Hepatitis A and/or Hepatitis B infections.
Advantagously the hepatitis vaccine composition of the invention contains
other
antigens so that it is effective in the treatment or prophylaxis of one or
more other
bacterial, viral or fungal infections.
Accordingly the hepatitis vaccine formulation according to the invention
preferably
contains at least one other component selected from non-hepatitis antigens
which are
known in the art to afford protection against one or more of the following:
diphtheria, tetanus, pertussis, Haemophilus influenzae b (Hib), and polio.
Preferably the vaccine according to the invention includes HBsAg as
hereinabove
defined.
Particular combination vaccines within the scope of the invention include a
DTP
(diphtheria-tetanus-pertussis) -hepatitis B combination vaccine formulation,
an Hib-
Hepatitis B vaccine formulation, a DTP-Hib-Hepatitis B vaccine formulation and
an
IPV (inactivated polio vaccine) -DTP-Hih-Hepatitis B vaccine formulation.
The above combinations may advantageously include a component which is
protective against Hepatitis A, especially the killed attenuated strain
derived from the
HM-175 strain as is present in Havrix.
Suitable components for use in such vaccines are already commercially
available and
details may be obtained from the World Health Organisation. For example the
IPV
component may be the Sally inactivated polio vaccine. The pertussis vaccine
may
comprise whole cell or acellular product.
Advantageously the hepatitis or combination vaccine according to the invention
is a
paediatric vaccine.
!91 i!»TITI ITG L~(JG'L~"
CA 02132833 2002-09-05
-6-
Vaccine preparation is generally described in New Trends and Developments in
Vaccines, edited by Voller et al., University Park Prcss, Baltin~oze, Maryland
U.S.A.
1978. Encapsulation within liposomes is described, for example, by Fullerton,
US
Patent 4,235,877. Conjugation of proteins to macromoloecules is disclosed, for
example, by Likhite, US Patent 4,372,945 and by Armor et al., US Patent
4,474,757.
The amount of antigen in each vaccine dose is selected as an amount which
induces
an immunoprotective response without significant, adverse side effects in
typical
vaccinecs. Such amount will vary depending on which specific immunogens are
employed. Generally it is expected that each dose will comprise 1-1000ug of
total
immunogen, preferably 2-100ug, most preferably 4-40ug. An optimal amount for a
particular vaccine can be as~cenained by standard studies involving
observation of
antibody titres and other responses in subjects. Following an initial
vaccination,
subjects may receive a boost in about 4 weeks.
In a further aspect of the present invention there is provided a method of
manufacture
of a vaccine effective in preventing or u~easing hepatitis infection, wherein
the method
comprises mixing the hepatitis antigen as defined herein with a carrier and
MPL.
Using this method one or more additional components arc preferably admixed
with
HBsAg to provide a combination vaccine, advantageously for paediatric use.
~ ~e drawings Figure 1 illustrates the seroprotection rate of MPL-HBV vaccine
when
compared with Engerix-B.
CA 02132833 2002-09-05
- 7
Example 1: Hepatitis B vaccine formulation
MPL was obtained from Ribi Immunochem Research Inc. Aluminium hydroxide was
obtained from Superfos (Alhydrogel).
S
MPL was resuspendcd in water for injection at a concentration varying from 0.2
to 1
mg/ml by sonication in a water bath until the particles mach a size of between
80 and
500 nm as measured by photo correlation light scattering.
1 to 20ug of HBsAg (S- antigen as in Engcrix B) in phosphate buffo solution at
lmgfml) is adsorbed on 30 to 100ug of aluminium hydroxide (solution at 10.38
Al3+
mg/ml) for one hour at room temperature under agitation. To the solution is
then
added 30 to SOug of MPL (solution 1 mg/ml). Volume and osmolarity are adjusted
to 600u1 with water for injection and phosphate buffer 5x concentrated.
Solution is
incubated at room temperature for 1 hour and kept at 4oC until use. Maturation
of
the formulation occurs during storage. This represents 10 injecting doses for
testing
in mice.
A similar formulation may be prepared by using as the HBsAg component the
composite (L*,S) antigen as defined hereinabove.
Example 2: Hepatitis A vaccine formulation
MPL was obtained from Ribi Immunochem Research Inc. Aluminium hydroxide was
obtained from Superfos (Alhydrogel).
HAV (360 to 22 EU per dose) is prcadsorbed on 1096 of the aluminium hydroxide
final concentration (O.Smg/ml). MPL ( 12.5 to 100ug per dose) is added to the
solution.
The remaining aluminium hydroxide is addod to the solution and left for one
hour at
room temperature. Volumes are adjusted with phosphate buffer (phosphate IOmM,
NaCI 150mM) and the final formulation is then stored at 4oC until use.
Example 3: Combination vaccine formulation - Hepatitis B +Hepatitis A
*Trade-mark
WO 93/19780 PCT/EP93/007~
_g_
HBsAg is adsorbed on 90°~ of the final amount of aluminium hydroxide
(O.Smg/ml)
and incubated overnight at room temperature. The pH is adjusted to 6.2 and the
preparation is left 14 days at room temperature for maturation.
Hepatitis A antigen at 360 to 22EU per dose, is"the form of an inactivated
derivative
of the HM-175 strain (as in Havrix) is preadSOrbed on 10% of the aluminium
hydroxide final concentration (O.Smg/ml}, vThe remaining aluminium hydroxide
is
then added to the solution and left for one hour at room temperature under
agitation.
The HAV adsorbed on aluminium hydroxide is then added to the HBsAg
formulation.
MPL is added to the HAV/HBsAg solution at a final concentration of 12.5 to
100ug
per 1 ml dose, the volume is adjusted to the final dose volume, and the
formulation is
stored at 4oC until used.
Example 4: Combination vaccines containing additional antigens
Combination vaccines containing DTP, IPV, Hib or acellular or whole cell
pertussis
antigens are prepared by adding one or more of the desired antigens to the
formulations described in Example 1, Example 2 or Example 3 above.
Example 5
INCREASE OF HUMORAL IMMUNITY AND INDUCTION OF CELL
MEDIATED IMMUNTTY BY IM11~UNIZATION OF MICE WTTH
HBsAgFORMULATED WITH ALUMINIUM HYDROXIDE AND MPL
A. EFFECT OF AI(OH)3 + MPL ON INDUCTION OF ANTI-HBs
ANTIBODIES
Balb/c mice were immunized by the subcutaneous route or by the intradermal
route
with recombinant HBsAg adsorbed on Al(OH)3 with MPL as adjuvant. Mice were
immunized twice with HBsAg/AI/MPL formulations and the antibody response was
measured after the first and the second doses. Total Ig were measured by ELISA
or
AUSAB kit (Abbott Lab, Ill.) and a particular attention was given to the
induction of
antibodies of the IgG2a isotype since this isotype is mainly induced by
secretion of g-
Interferon. The induction of this isotype thus indirectly reflects the
activation of cell
mediated immunity, namely the activation of Thl.
The ratio HBsAg/MPL has been investigated as well as the size of MPL particles
since suspension of MPL in water can result in particles of < 100 nm or > 500
nm.
Q! se'c~r~r~ FTC CuccT
~O 93/19780 ~,~, PCT/EP93/00712
-9-
EXPERIMENT I - Effect of MPL (> 500 nm) dose on immunogenicity of
rec.HBsAg adsorbed on Al(OH)3
Groups of 10 female Balb/c mice were injected by the subcutaneous route with
2.5
mcg of recHBsAg adsorbed on 50 mcg of Al+++ (as Al(OH)3) and increasing
amounts of MPL (3.1 to 50 mcg) with a particle size of > 500 nm. The mice were
injected twice in a volume of lOQ mcl and at 2 weeks interval. They were bled
2
weeks after the first injection (partial bleeding) and one week after the
booster. Total
anti-HBs IgG and specific IgG2a were measured by 13,.ISA using recHBsAg as
capture antigen. The titers were expressed as the reciprocal of the dilution
corresponding to 50 9b of the maximal value (mid-point dilution). The results
are
given at table 1. They indicate an increase of both specific IgG and IgG2a
with
increasing doses of MPL, particularly for doses of 12.5 to 50 mcg. The effect
is seen
for both primary and secondary responses and is particularly obvious for IgG2a
(up to
fold increase) indirectly indicating a secretion of g-interferon induced by
the
immunization with MPL.
EXPERIMENT II ~ Comparison of clinical lots of adsorbed recHBsAg
20 containing or not containing MPL (> 500 nm)
3 clinical lots of recHBsAg adsorbed on Al(OH)3 were prepared : lot DSAH16
contained no MPL and served as control. Lots DSAR501 and 502 were prepared in
a
similar way (20 mcg of recHBsAg adsorbed on 0.5 mg Al+++ as Al(OH)3) but
contained 50 mcg of MPL (> 500 nm).
The 3 lots were injected subcutaneously to groups of 10 mice (200 mcl
containing 2.5
mcg HBsAg, 100 mcg Al+++ and 6.25 mcg MPL), twice at 2 weeks interval. The
mice were bled at day ~ 14 and 1 week after the booster. Anti-HBs antibodies
were
measured using AUSAB kit or an in-house ELISA for either IgG or IgG2a. The
results are given in table 2. They indicate that, 2 weeks after the first
injection, the 2
lots containing MPL induce a very significant anti-HBs response (12.4 and 41.9
mIU/ml) while the lot which does not contain MPL only induces a marginal
response
(0.75 mILT/ml). The number of responders is also higher with MPL (9/10 and
9/10
versus 1/10 in absence of MPL). The effect of MPL is confirmed after the
booster
since the titers obtained for lots DSAR501 and 502 are about 6 fold higher
than that
observed without MPL.
This indicates that, at least in mice, MPL (> 500 nm) can improve both the
kinetics of
the anti-HBs response and the level of the anti-HBs response.
These results were confirmed when specific IgG and IgG2a are measured after
immunization with lots DSAH16 (without MPL) and DSAR502 (with MPL): the anti-
Q~~il~eTfT1 tTC LUCCT
WO 93/19780 Q'~ '~ PCT/EP93/0071~
- 10-
HBs IgG titer is 5 (primary response) and 3 (secondary response) times higher
when
MPL is present.
For the IgG2a response, the effect of MPL is even more striking, at least
after the
second dose, indicating a preferential induction of IgG2a. This indirectly
reflects
activation of cell-mediated immunity (secretion of g-interferon) by the
preparation
containing MPL.
EXPERIMENT III - Effect of MPL (< 100 nm) dose on immunogenicity of
eecHBsAg adsorbed on Al(OH)3
Because MPL is much easier to obtain in a reproducible way as < 100 tun than
as >
500 nm particles, the effect of < 100 nm MPL particles on the immunogenicity
of
recHBsAg previously adsorbed on Al(OH)3 was investigated.
Groups of 10 mice (Balb/c, female, 7 weeks old) were injected subcutaneously
with 1
mcg of recHBsAg adsorbed on 50 mcg of Al+++ (as Al(OH)3) and in presence of
increasing amounts (3.1 to 25 mcg) of MPL(< 100 nm). The mice were injected
twice at 2 weeks interval with a volume of 200 mcl. They were bled 2 weeks
after
the first injection and 1 week after the booster. The anti-HBs response was
evaluated
by ELISA (total Ig, IgG, IgG2a) on pooled sera. The titers were expressed as
mid-
point dilutions (reciprocal of the dilution giving 50 R°o of the
highest values). The
results indicate that as few as 3.1 mcg of NiPL induce a strong increase of
the
antibody response both for primary and secondary responses. The response
culminates for 6.25 mcg and decreases afrerwards to become similar to that
found
without MPL when high doses of NiPL (25 mcg) are used. The pattern of the
antibody response is similar for IgG, IgG2a and total Ig. It contrasts with
results
obtained for MPL of higher size (> 500 nm) (see experiment n and suggests that
small size (< 100 nm) particles of MPL are more effective than larger size (>
500 nm)
particles (at least for humoral immunity), since less MPL is needed to obtain
the
maximal effect. The highest activity of small size MPL was confirmed in
several
experiments.
As shown for larger size MPL (> 500 nm), the adjuvant effect of MPL is higher
for
IgG2a than for total IgG or Ig. At the maximal effect of the secondary
response (6.25
mcg of MPL), there is a 25 fold increase for IgG2a while the
increase for IgG or total Ig was 7.6 and 4.3 respectively.
B. INDUCTION OF CELL-MEDIATED IMMUNTTY BY recHBsAg
ADSORBED ON Al(OH)3 - EFFECT OF MPL
If humoral immunity is sufficient to protect against Hepatitis B, the
induction of cell-
mediated immunity (CTL, Thl) could be of particular importance for the
treatment of
the disease.
t?1 ~a~TIT1 ITC CtJCCT
~ ~~3~~33
O 93/19780 PCT/EP93/00712
-11-
New formulations are required however for therapeutic vaccines since Al(OH)3
is
capable of improving humoral immunity but not cell mediated immunity.
We have investigated the effect of MPL on the induction of Thl cells capable
of
secreting IL-2 and g-(i.e, gamma) interferon in Balb/c mice immunized with
recHBsAg adsorbed on Al(OH)3.
EXPERIMENT I - Effect of MPL (> 500 nm) on induction of Thl cells after
immunization of Balb/c mice with Al(OH)3 adsorbed HBsAg
A group of 10 Balb/c mice (female, 5 weeks old) were immunized by injection in
each footpad of 30 mcl containing 10 mcg of HBsAg, 15 mcg of Al+++ (as
Al(OH)3)
and 15 mcg of MPL. Control mice were injected similarly with the same amount
of
recHBsAg either mixed with FCA (positive control) or adsorbed on Al(OH)3
without
MPL (negative control).
Six days after the immunization, the mice were killed and the popliteal lymph
nodes
were removed. The lymph node cells (LNC 2.105/m1) were cultivated for
different
periods of time (24 hrs to 74 hrs) in RPMI medium supplemented with 1 % of
negative mouse serum and containing 5 mcg/ml of recHBsAg. After termination of
the culture, the amount of IL-2, INF-g and IL-4 secreted in the medium was
measured. IL-2 was estimated by its ability to stimulate the proliferation
(evaluated
by incorporation of 3H-Thymidine) of an IL-2-dependent CTL line (VDA2 cells)
and
the titer was expressed as stimulation index (SI = amount of 3H-Thymidine
incorporated in stimulated cells/amount of 3H-Thymidine incorporated in non
stimulated cells). The amount of IL-4 and INF-g was measured using commercial
ELISA kits (Holland Biotechnology for 1FN-g and Endogen for ILr4). The titers
were expressed in pg of IFN-g/ml.
The results indicate that no significant amount of IL-2, IL-4 or 1NF-g is
secreted by
LNC from mice immunized with HBsAg adsorbed on Al(OH)3. On the contrary,
high lcvels of IL-2 (LS. = 38 at 48 hrs) and a significant amount of INF-g are
secreted by LNC from mice immunized with HBsAg adsorbed on Al(OH)3 + MPL.
This secretion is similar (INF-g) or higher (11.-2) to that observed for mice
immunized with HBsAg + FCA and the in vitro secretion occurs earlier.
No IL-4 was detected after immunization with HBsAg adsorbed on Al(OH)3 even in
presence of MPL.
This secretion profilc indicates that specific Thl cells (11.-2, INF-g) have
been
induced by immunization with adsorbed HBsAg in presence of MPL but not in
absence of MPL. However, no Th2 (ILr4) were detected in these conditions of
immunization.
e~~ arse-r~-~-~ ~T= cuCC~r
WO 93/ I 9780fr ~~ ~ ~ ~ ~ PCT/ EP93/007
- 12-
EXPERIMENT II - Effect of the dose of MPL (< 100 nm) on the induction of
Thl cells after immunization of Balb/c mice with AI(OH)3 adsorbed recHBsAg
Groups of 5 Balb/c mice were immunized in each of the 2 footpads with30 mcl
containing 10 mcg of recl-iBsAg adsorbed, on 15 mcg of Al+++ (as Al(OH)3) and
with increasing amounts of NiPL ( 100 ~nm, 0 to 15 mcg).
Six days after the injection, the mice were killed and the popliteal lymph
node cells
(LNC) were cultivated at 2.106 cells/ml in RPMI supplemented with 1 °k
negativc
mouse serum for different periods of time (24 hrs to 96/25) in presence of 5
mcg/ml
of recHBsAg.
The secretion of IL-2 was measured by stimulation of the proliferation of VDA2
cells
and concentration of IL-2 is expressed as Stimulation Index (SI); the
secretion of
INF-g was measured using a commercial kit and expressed in pg/ml.
It was found that the secretion of IL-2 is dramatically increased by the lower
dose of
MPL (7.5 mcg) and a maximal effect is obtained for 15 mcg of MPL.
The secretion of IL-2 is generally more important at 24 hrs than at 48 or 72
hrs.
The secretion of INF-g is absent when HBsAg is adsorbed on Al(OH)3 in absence
of
MPL. A small dose (7.5 mcg) of MPL induces a secretion of INF-g and again, the
maximal effect is obtained for 15 mcg of MPL. Contrary to what is observed for
IL-
2, the secretion of INF-g is delayed in the culture and increases with time up
to 96
hours.
Taken together these data indicate that MPL (100 nm) is a potent inducer of
Thl
when combined with HBsAg adsorbed on AI(OH)3.
C. CONCLUSION
The effect of a formulation containing HBsAg adsorbed on Al(OH)3 and MPL on
the
induction of both humoral and cell-mediate immunity in Balb/c mice has
been investigated. The results indicate that MPL clearly improves the kinetics
of the
anti-HBs response since much more anti-HBs antibodies are found after both the
primary and secondary immunizations. The quality of the anti-HBs is also
modified
and a preferential induction of IgG2a has been observed, reflecting indirectly
secretion of INF-g and thus induction of a cell-mediated immunity.
Direct evaluation of the induction of Thl cells by formulations containing
HBsAg,
Al(OH)3 and MPL clearly indicates that MPL is a potent inducer of Thl
Q~ se~~-r~i-~ FTC ~ucc-r
~ " 21328~~
~O 93/19780' PCT/EP93/00712
-13-
cells secreting both II~2 and INF-g. This kind of formulation is thus
important in the
development of therapeutic vaccines.
For Tables showing the results of experiments described above, see Tables 1 to
6
below.
Example 6
CLINICAL USE OF MPL AS ADJUVANT TO HBsAg- -Preliminary results
Study MPL-HBV-002 (ongoing)
This study compares HBsAg-MPL to Engerix-B in young healthy unprimed adult
volunteers.
End points
- Immunogenicity : magnitude of anti-HBs antibodies response
- Kinetics of anti-HBs antibody response
- Cell-mediated immunity induced by both vaccines (in vitro and in vivo).
- Reactogenicity, toxicology and safety.
Material and methods
a) Vaccines
HBsAg (as in Alum MPL
Engerix B)
I 20ug SOOpg 50pg
II 20pg SOOpg None
b) Population
* Healthy adult volunteers, between 18 and 30 years of age.
* They must be negative for HBV markers and must never have been vaccinated
against hepatitis B.
c) Design
- Double-blind, randomized study.
- Schedule of vaccination : 0,1,6 months
c~~ se'~~-~~-, FTC ouc~c~-
WO 93/19780 PCT/EP93/007
- 14-
~~36zg33
- Follow-up till month 12.
- Blood sampling
* Anti-HBs antibody testing is donebefore, 7 days, 15 days, 30 days after each
vaccination.
15
,..'~:, t
* Biochemistry and haematoiogy parameters are evaluated before and 2 days
after each dose.
* Blood for evaluation of the cell-mediated immunity is taken before and after
the primary vaccination course and the booster dose.
- Reactogenicity
The subjects are required to record occurrence of local and general signs and
symptoms on diary cards on the day of vaccination and during the 7 following
days.
Results
The results up to 2 months after the second dose are given below.
Population
A total of 29 subjects have given their informed consent but only 27 - 15 male
and 12
female - met the entry criteria. 1 S subjects were allocated to Group I and 12
to Group
II. The mean age was 22 years.
Safety
35
No serious adverse experience was reported and no subjects were withdrawn or
had to
be withdrawn from the study. No clinically significant modification of the
haematological or biochemical parameters were observed. The incidence and
severity
of local and general signs and symptoms is similar in both vaccine groups.
Immunogenicity:
The anti-HBs antibody titres have been measured up to day 90, ie 2 months
after the
second dose. The seroconversion rate (SC, in %) is defined as the appearance
of
antibodies in initially seronegative subjects.
The seroprotection rate is defined as the percentage of subjects with
protective anti-
HBs antibody titres. If there seems to be no clear difference in the magnitude
of the
antibody response with GMTs comparable between the two groups, the kinetics of
the
Q1 i~G~TIT1 ITG cU~CT
~13~~33
~O 93/19780 PCT/EP93/00712
- 15-
response is different and there is a clear advantage of the vaccine containing
MPL.
Indeed, 7 days after the second dose, 93% and 80% of the subjects receiving
the
NiPL-HBV vaccine seroconverted and were protected respectively in comparison
with
a seroconversion rate of 95°1o and a seroprotection rate of
58°!o in the Engerix-B
group. This difference is maintained up to two months after the second dose
and is
particularly evident for the seroprotection rate. At this time point, all
subjects who
received the MPL-I-iBV vaccine are protected in comparison with 58°!0
of the subjects
vaccinated with the alum adjuvanted vaccine.
Study MPL-HBV-003 (ongoing)
The material and methods are similar to those of MPL-HBV-002 study (see
above).
The schedules of vaccination are different
Group No of subjects Vaccine Schedule
25 MPL- 0-2 months
HBsAg/alum
II 25 Engerix-B 0-2 months
III 25 MPL- 0-6 months
HBsAg/alum
IV 25 Engerix-B 0-6 months
Results
Although the kinetics of the anti-HBs antibody response has not been followed
as
closely as in the previous study, it appears that the same conclusion can be
drawn in
the present study. The subjects who receive the MPL adjuvanted vaccine respond
better after the second dose than those injected with the vaccine without MPL.
All but
one subject (95.8°k) have protective titres one month after the second
dose of MPL-
HBV vaccine, as compared with 72.7~'o in the Engerix-B group. Furthermore, in
contrast with the previous trial, the MPL-HBV vaccine seems to induce higher
antibody titres than Engerix-B (214 and 72 mIU/ml, respectively) indicating
that a
longer interval between the doses is perhaps important.
Conclusions
In these two studies, the hepatitis B vaccine (containing I3BsAg as in Engerix
B and
alum) adjuvanted with MPL was evaluated in healthy adult volunteers and
compared
to Engerix-B (HBsAg S-antigen formulated with alum) according to various
e~ so~T~r~ FTC cuccr
CA 02132833 2002-09-05
- 16-
schedules. If there seems to be no difference in immunogenicity between the
two
vaccines after one dose, the MPL-HBV vaccine shows a clear advantage after the
second dose, especially with a much higher percentage of subjects with
protective .
antibody titres. The GMTs are also higher in this group when the two doses arc
given
at two months interval instead of one month.
This could indicate a better priming of the icsponse when MPL is added to the
antigen. Such a vaccine would therefore be of great value in slow or low
responders
to hepatitis B vaccination, such as older people or immunocompromised
subjects.
For Tables showing the results of the experiments described above, see Tables
7.
and 8 and Figure 1.
Example 7
HEPATTT1S A - MPL STUDY IN MICE
The following experiment demonstrates that addition of MPL to Hepatitis A
vaccine
has a beneficial effect: This is reflected in a lower ED50-value (dose,
expressed in
ELISA units -Ell-, that gives a serological response in 50% of the animals
injected).
METHOD
NMRI mice were injected with 1 dose of experimental HAV vaccine containing 360-
120-40-13.3 EU/dose combined with different concentrations of MPL (0-1.5-6-
12.5
pg/dose). Blood samples were taken 28 days after inoculation and the serum
tested in
the HAVAB test (using a 2096 cutoff). The ED50 (expressed in Ell) was
calculated
and corresponds to the dose that induces a serological response in SOqb of the
animals
tested.
RESULTS
Results arc summarized in the following Table. The vaccine containing no MPL
had
an ED50 of 123.7 Ell, whereas the vaccine containing 1.5 pg MPLldose had an
ED50
of 154. Higher doses of MPL had a beneficial affect (the ED50 was observed at
lower Ell values). At 12.5 pg MPLJdose, the ED50 observed was 47.1 Ell.
CONCLUSION
The combination of the appropriate amount of MPL to HAV-vaccine improves the
performance of this vaccine when tested in the mouse potency assay.
0-6 months
~~~~833
93/19780 PCf/EP93/00712
- 17-
TABLE : Effect of the addition of MPL to Hepatitis A vaccine
Dose of MPL added to HAV-vaccine ED50 (in EU/dose)
(pg/dose)
0 123.7
1.5 154
101.1
12.5 47.1
w ses~r~T~ mr~ cu~cT
WO 93/1970 < PCT/EP93/007~
213 ~g~ ~
-18-
TABLE 1
EFFECT OF INCREASIN -~ DOSES OF MPL (>500 NMl
QN Il~~:h~LJNO tENICITY OF RFCHBSO,G ADSORB -D ON ALIOHI~
w
Amount of Ariti~HBs
response
MPL
(mcg/dose)
Total IgG2a
IgG
Da 14 Day 21 Da 14 Day 21
0* 69 743 3.2 11
3.13 122 541 3.8 20
6.25 296 882 6.4 24
12.5 371 1359 10 48
25 456 1493 18 138
50 403 1776 33 242
*HBsAg on Al
w ses~T~r~ mr~ cuCCT
_ ~132~3~~
93/19780 PCT/EP93/00712
- 19-
TABLE 2
COMPARISON OF .LINICAL LnT. ONTAINING nR NOT MPl
AUSAB RESPONSE
Lot Dose of Dose of GMT Anti-HBs
HBsAg MPL (mIU/ml)
on
Al(OH)3 (mcg)
(mcg)
DSAH16 2.5 0 0.75 15.1
DSAR501 2.5 6.25 12.4 96.7
DSAR502 2.5 6.25 41.9 89.2
TABLE 3
(_'.OMPARISON OF 2 .1.TNT('A~. 1.OT. ONTAININ(~ OR NOT MP
(>500NM)
AL~ITI-HBO Ic: . AND IcG2A RESPONSE
Lot Dose of Dose of Anti-HBs
response
HBsAg MPL
on
Al(OH)3 (mcg)
(mcg)
IgG IgG2a
d15 d21 d15 d21
DSAH16 2.5 0 20 178 <5 5
DSAR502 2.5 6.25 113 641 <5 28
Q110CTIT1 ITC CU=GT
WO 93/19780 PCT/EP93/007~
2.~3~g~3
-20-
TABLE 4
rr.~rn~r n~ wROt ~mnn wrA~1 T1llC>;' 11N IMM1TN(1(:FNT('TTY (1f RFf HB~A
Frr L1 yr lrlrLW vm.i.mam~r~~
,ADSORBED ON AL(OHI~
Dose Dose ? Anti-HBs
of response
HBsAg oMPLf
on
Al(OH)3 (<100nm)
(mcg) (mcg)
Total I G I G2a
I
d15 d21 d15 d21 d15 d21
1 0 30 637 67 516 15 99
1 3.12 312 2302 335 3532 167 1752
1 6.25 538 2719 856 3932 261 2521
1 12.5 396 2104 485 3625 125 1393
1 25.0 38 446 141 638 28 233
Q'sn~°rvrv vTS= cucCT
,~ 2.~3~833
!I0 93/19780 PCT/EP93/00712
- 21 -
E
0
,~ V_
~
_
U (1a
C
."' U
U a.
U
c,..,O
U
E-'E-'~ ~ ~ N
z z ~. v
m
z z
v v
U
N
N
V
s Q
~ C
O t o ~ ~ o
0 o
M V V N >
O ~ "'
~
U V~ N t!7 U U
V N N N ~
t U Q.
V _ _
V V
N
N N N CJ
_ _ _ _ U
.--. V V V V ~ "
N b
~.
C N
C ~ ~ C ..c y
Q N 00 C
a.
G7~~ >' ~?
~
""' 3
~ K
Gy C oc~t oo
L M ~ '~t
....._.
U
t r~
C '~
L M t~C N ...
c~
'
C
N ~..p -
~ LL
'
~ z
O ~ M '-'01 .O N
U U p _ c
z
. ~
~1ru.v ~ ~ 0 C ~'_'
M O O
a .
a ~ o
N
_ ~U..
.~
_ U
U
~
O Q N ~ ~ N ' t
E
4.
~ '
Q O 0~ c,., C
E- v z a
~
Q~ s~n~~r-~~-~ ~~-c cu~c~
WO 93/19780 PCT/EP93/007
- 22 -
~1~~,~33
~,.,
"", vC V ~C~~',N
a
a
v ~ N v
,.
O ~ x ~ N 00 \V
z
0
N
O
V ~> .. ~ x ~C ~G
N t<;M M
G
x ~,
Gi, N ~ N ~ I~ tn
i
Gi:
t N N N
'fit
N
c
a ...~?~ O
- V ~ ~ m
c
LT. C
G c.
tz
..
o v
C N N N N
Q O CO
Er
et~ so~T~~-s FTC cuccT'
93/19780 - ~ ~ ~ ~ ~ ~ ~ PCT/EP93/00712
- 23 -
Z
E
U
E-
O
Q O p ~ ~ O M ~ O O p ~ O M t~ O M
~CO M O O ~ ~ 00~ O 00
/~ Gtr O O t~ N 00 I~00 ~ C O N N tn!!'l!~V~
J C <t ~ ~? ~ N V~O N Ov M N M M
> Gz:
N .
~ Q
O
v a Z ~ T C p O O O O M
> C'L O C r. O O ~ ~ '~
'S ~ ~ ~ e1 CV0M1~ O C M O V'itW p M
O O M ~ t~00 vDOp
J
2
N N N N N N N N
~. . ...i...~. .....,.-,..r.....,~. ~..~ ~...
r
..
_ ~ W O ~ ~ ~ ~ ~ y O
r.. t~..~t<) t~ ~ M ~ ~
O .~ '~'~OO '~ 'L7y .~ '~'~ a
j ~.r~ ~r ~.r'r~r
c L ~ a ,
- c. . a, c , , . a. c. c.a. c..
": n
z =
~L
J ,_,,~ ~, ~n
r.,
> t Gz7
s
J
C~ v
Q
Vi r
1r
CTf ~f:~CTiTt 1TC CIJCOT
CA 02132833 2002-09-05
.- 24
TABLE 8
MPL-HBV-003 STUDY
Group Vaccine Timing N SC(%) GMT SP (%)
I MPL- Pre 25 0.0 0 0.0
HBsA? Pl(ml) 23 56.5 10 26.1
(?U~g) P 1 (m2)24 66.7 6 16.7
P2(m3) 24 100.0 214 95.8
II Engerix-BPre 25 0.0 0 0.0
(20~tg) Pl(ml) 24 41.7 12 29.2
P1 (m2) 19 52.6 4 5.3
P2(m3) 22 90.9 72 72.7
